Research programme: autoimmune disease therapeutics - Toleranzia

Drug Profile

Research programme: autoimmune disease therapeutics - Toleranzia

Alternative Names: multiple sclerosis tolerogen; myasthenia gravis tolerogen; rheumatoid arthritis tolerogen; TOL 1; TOL 2; type 1 diabetes mellitus tolerogen

Latest Information Update: 08 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toleranzia
  • Class Proteins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Myasthenia gravis
  • Research Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 01 Nov 2016 Toleranzia has patent protection for its tolerogenic platform in USA
  • 31 Oct 2016 Toleranzia applies for Orphan Drug status for TOL 2 in Myasthenia gravis in USA
  • 21 Oct 2016 Toleranzia and Hellenic Pasteur Institute agree to co-develop TOL 2 for Myasthenia gravis before October 2016 (9206447; 9206424)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top